Abstract:Under different pathophysiological conditions, endothelial cells lose endothelial phenotype and gain mesenchymal cell-like phenotype via a process known as endothelial-to-mesenchymal transition (EndMT). At the molecular level, endothelial cells lose the expression of endothelial cell-specific markers such as CD31/platelet-endothelial cell adhesion molecule, von Willebrand factor, and vascular-endothelial cadherin and gain the expression of mesenchymal cell markers such as α-smooth muscle actin, N-cadherin, vimentin, fibroblast specific protein-1, and collagens. EndMT is induced by numerous different pathways triggered and modulated by multiple different and often redundant mechanisms in a context-dependent manner depending on the pathophysiological status of the cell. EndMT plays an essential role in embryonic development, particularly in atrioventricular valve development; however, EndMT is also implicated in the pathogenesis of several genetically determined and acquired diseases, including malignant, cardiovascular, inflammatory, and fibrotic disorders. Among cardiovascular diseases, aberrant EndMT is reported in atherosclerosis, pulmonary hypertension, valvular disease, fibroelastosis, and cardiac fibrosis. Accordingly, understanding the mechanisms behind the cause and/or effect of EndMT to eventually target EndMT appears to be a promising strategy for treating aberrant EndMT-associated diseases. However, this approach is limited by a lack of precise functional and molecular pathways, causes and/or effects, and a lack of robust animal models and human data about EndMT in different diseases. Here, we review different mechanisms in EndMT and the role of EndMT in various cardiovascular diseases.

Endothelial-to-Mesenchymal Transition in Cardiovascular Pathophysiology

Endothelial-to-mesenchymal Transition: A Novel Therapeutic Target for Cardiovascular Diseases

The Role of Endothelial-to-Mesenchymal Transition in Cardiovascular Disease

Endothelial to mesenchymal transition in cardiovascular diseases: Developmental signalling pathways gone awry.

Endothelial to Mesenchymal Transition in Pulmonary Vascular Diseases

TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering

The Therapeutic Potential of Targeting the Endothelial-to-mesenchymal Transition

In Brief: Endothelial-To-Mesenchymal Transition

Endothelial-to-mesenchymal transition: Pathogenesis and therapeutic targets for chronic pulmonary and vascular diseases

Acetate Controls Endothelial-to-mesenchymal Transition

The Role of Endothelial–mesenchymal Transition in Development and Pathological Process

Endothelial Mesenchymal Transition in Cardiac Fibrosis

EndMT: A promising and controversial field

Endothelial-to-mesenchymal transition: New insights into vascular calcification

Research progress of endothelial-to-mesenchymal transition

Histone modification of endothelial-mesenchymal transition in cardiovascular diseases

Experimental Models to Study Endothelial to Mesenchymal Transition in Myocardial Fibrosis and Cardiovascular Diseases

Advances in regulating endothelial-mesenchymal transformation through exosomes

Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability

Transforming Growth Factor β–Induced Endothelial-to-Mesenchymal Transition: A Switch to Cardiac Fibrosis?

Advancement of Endothelial-to-mesenchymal Transition in Cardiovascular system